Platelet factor-4 (CXCL4/PF-4): An angiostatic chemokine for cancer therapy

Cancer Letters

Volumn 331, Issue 2, 2013, Pages 147-153

  Wang, Zhe ^a   Huang, He ^a  

^a TIANJIN UNIVERSITY   (China)

Author keywords

Angiogenesis; Cancer therapy; Platelet factor 4

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR3B; FIBROBLAST GROWTH FACTOR 2; INTEGRIN; INTERLEUKIN 8; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG; VASCULOTROPIN 121; VASCULOTROPIN 165;

ANTIANGIOGENIC ACTIVITY; CELL CYCLE; CELL DIFFERENTIATION; COLON CARCINOMA; DRUG MECHANISM; GENE STRUCTURE; GLIOMA; GRANULOCYTE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MELANOMA; MONOCYTE; MYELOMA; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN INDUCTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SHORT SURVEY; T LYMPHOCYTE;

EID: 84875370042     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.01.006     Document Type: Review

References (69)

1. Deutsch E., Johnson S.A., Seegers W.H. Differentiation of certain platelet factors related to blood coagulation. Circ. Res. 1955, 3:110-115.
2. Slungaard A. Platelet factor 4: a chemokine enigma. Int. J. Biochem. Cell Biol. 2005, 37:1162-1167.
3. Maione T.E., Gray G.S., Petro J., Hunt A.J., Donner A.L., Bauer S.I., Carson H.F., Sharpe R.J. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990, 247:77-79.
4. Maione T.E., Gray G.S., Hunt A.J., Sharpe R.J. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res. 1991, 51:2077-2083.
5. Kolber D.L., Knisely T.L., Maione T.E. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J. Natl. Cancer Inst. 1995, 87:304-309.
6. Eisman R., Surrey S., Ramachandran B., Schwartz E., Poncz M. Structural and functional comparison of the genes for human platelet factor 4 and PF4alt. Blood 1990, 76:336-344.
7. Poncz M., Surrey S., LaRocco P., Weiss M.J., Rappaport E.F., Conway T.M., Schwartz E. Cloning and characterization of platelet factor 4 cDNA derived from a human erythroleukemic cell line. Blood 1987, 69:219-223.
8. Tunnacliffe A., Majumdar S., Yan B., Poncz M. Genes for beta-thromboglobulin and platelet factor 4 are closely linked and form part of a cluster of related genes on chromosome 4. Blood 1992, 79:2896-2900.
9. Deuel T.F., Keim P.S., Farmer M., Heinrikson R.L. Amino acid sequence of human platelet factor 4. Proc. Natl. Acad. Sci. USA 1977, 74:2256-2258.
10. 1H NMR spectroscopy. Biochemistry 1989, 28:9469-9478.
11. Rabellino E.M., Levene R.B., Leung L.L., Nachman R.L. Human megakaryocytes. II. Expression of platelet proteins in early marrow megakaryocytes. J. Exp. Med. 1981, 154:88-100.
12. de Jong E.K., de Haas A.H., Brouwer N., van Weering H.R., Hensens M., Bechmann I., Pratley P., Wesseling E., Boddeke H.W., Biber K. Expression of CXCL4 in microglia in vitro and in vivo and its possible signaling through CXCR3. J. Neurochem. 2008, 105:1726-1736.
13. McLaren K.M., Holloway L., Pepper D.S. Human platelet factor 4 and tissue mast cells. Thromb. Res. 1980, 19:293-297.
14. El Golli N., Issertial O., Rosa J.P., Briquet-Laugier V. Evidence for a granule targeting sequence within platelet factor 4. J. Biol. Chem. 2005, 280:30329-30335.
15. Niewiarowski S., Thomas D.P. Platelet factor 4 and adenosine diphosphate release during human platelet aggregation. Nature 1969, 222:1269-1270.
16. Kaplan K.L., Broekman M.J., Chernoff A., Lesznik G.R., Drillings M. Platelet alpha-granule proteins: studies on release and subcellular localization. Blood 1979, 53:604-618.
17. Schaffner A., Rhyn P., Schoedon G., Schaer D.J. Regulated expression of platelet factor 4 in human monocytes-role of PARs as a quantitatively important monocyte activation pathway. J. Leukocyte Biol. 2005, 78:202-209.
18. Files J.C., Malpass T.W., Yee E.K., Ritchie J.L., Harker L.A. Studies of human plate alpha-granule release in vivo. Blood 1981, 58:607-618.
19. Zucker M.B., Katz I.R. Platelet factor 4: production, structure, and physiologic and immunologic action. Proc. Soc. Exp. Biol. Med. 1991, 198:693-702.
20. Han Z.C., Sensebe L., Abgrall J.F., Briere J. Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Blood 1990, 75:1234-1239.
21. Lambert M.P., Rauova L., Bailey M., Sola-Visner M.C., Kowalska M.A., Poncz M. Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Blood 2007, 110:1153-1160.
22. Dudek A.Z., Nesmelova I., Mayo K., Verfaillie C.M., Pitchford S., Slungaard A. Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesis. Blood 2003, 101:4687-4694.
23. Piepkorn M.W. Dansyl (5-dimethylaminonaphthalene-1-sulphonyl)-heparin binds antithrombin III and platelet factor 4 at separate sites. Biochem. J. 1981, 196:649-651.
24. Scully M.F., Weerasinghe K., Kakkar V.V. Inhibition of contact activation by platelet factor 4. Thromb. Res. 1980, 20:461-466.
25. Dumenco L.L., Everson B., Culp L.A., Ratnoff O.D. Inhibition of the activation of Hageman factor (factor XII) by platelet factor 4. J. Lab. Clin. Med. 1988, 112:394-400.
26. Griffin J.H., Fernandez J.A., Gale A.J., Mosnier L.O. Activated protein C. J. Thromb. Haemost. 2007, 1:73-80.
27. Bebawy S.T., Gorka J., Hyers T.M., Webster R.O. In vitro effects of platelet factor 4 on normal human neutrophil functions. J. Leukocyte Biol. 1986, 39:423-434.
28. Hayashi N., Chihara J., Kobayashi Y., Kakazu T., Kurachi D., Yamamoto T., Nakajima S. Effect of platelet-activating factor and platelet factor 4 on eosinophil adhesion. Int. Arch. Allergy Immunol. 1994, 1:57-59.
29. Schiemann F., Grimm T.A., Hoch J., Gross R., Lindner B., Petersen F., Bulfone-Paus S., Brandt E. Mast cells and neutrophils proteolytically activate chemokine precursor CTAP-III and are subject to counterregulation by PF-4 through inhibition of chymase and cathepsin G. Blood 2006, 107:2234-2242.
30. Scheuerer B., Ernst M., Durrbaum-Landmann I., Fleischer J., Grage-Griebenow E., Brandt E., Flad H.D., Petersen F. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000, 95:1158-1166.
31. Fricke I., Mitchell D., Petersen F., Bohle A., Bulfone-Paus S., Brandau S. Platelet factor 4 in conjunction with IL-4 directs differentiation of human monocytes into specialized antigen-presenting cells. Faseb. J. 2004, 18:1588-1590.
32. Xia C.Q., Kao K.J. Effect of CXC chemokine platelet factor 4 on differentiation and function of monocyte-derived dendritic cells. Int. Immunol. 2003, 15:1007-1015.
33. Pervushina O., Scheuerer B., Reiling N., Behnke L., Schroder J.M., Kasper B., Brandt E., Bulfone-Paus S., Petersen F. Platelet factor 4/CXCL4 induces phagocytosis and the generation of reactive oxygen metabolites in mononuclear phagocytes independently of Gi protein activation or intracellular calcium transients. J. Immunol. 2004, 173:2060-2067.
34. von Hundelshausen P., Koenen R.R., Sack M., Mause S.F., Adriaens W., Proudfoot A.E., Hackeng T.M., Weber C. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005, 105:924-930.
35. Marti F., Bertran E., Llucia M., Villen E., Peiro M., Garcia J., Rueda F. Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8. J. Leukocyte Biol. 2002, 72:590-597.
36. Struyf S., Salogni L., Burdick M.D., Vandercappellen J., Gouwy M., Noppen S., Proost P., Opdenakker G., Parmentier M., Gerard C., Sozzani S., Strieter R.M., Van Damme J. Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood 2011, 117:480-488.
37. Liu C.Y., Battaglia M., Lee S.H., Sun Q.H., Aster R.H., Visentin G.P. Platelet factor 4 differentially modulates CD4+CD25+ (regulatory) versus CD4+CD25-(nonregulatory) T cells. J. Immunol. 2005, 174:2680-2686.
38. Romagnani P., Maggi L., Mazzinghi B., Cosmi L., Lasagni L., Liotta F., Lazzeri E., Angeli R., Rotondi M., Fili L., Parronchi P., Serio M., Maggi E., Romagnani S., Annunziato F. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J. Allergy Clin. Immunol. 2005, 116:1372-1379.
39. Mueller A., Meiser A., McDonagh E.M., Fox J.M., Petit S.J., Xanthou G., Williams T.J., Pease J.E. CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3. J. Leukocyte Biol. 2008, 83:875-882.
40. Sharpe R.J., Byers H.R., Scott C.F., Bauer S.I., Maione T.E. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J. Natl. Cancer Inst. 1990, 82:848-853.
41. Watson J.B., Getzler S.B., Mosher D.F. Platelet factor 4 modulates the mitogenic activity of basic fibroblast growth factor. J. Clin. Invest. 1994, 94:261-268.
42. Gengrinovitch S., Greenberg S.M., Cohen T., Gitay-Goren H., Rockwell P., Maione T.E., Levi B.Z., Neufeld G. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J. Biol. Chem. 1995, 270:15059-15065.
43. Perollet C., Han Z.C., Savona C., Caen J.P., Bikfalvi A. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood 1998, 91:3289-3299.
44. Bikfalvi A. Recent developments in the inhibition of angiogenesis: examples from studies on platelet factor-4 and the VEGF/VEGFR system. Biochem. Pharmacol. 2004, 68:1017-1021.
45. Javerzat S., Auguste P., Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol. Med. 2002, 8:483-489.
46. Handin R.I., Cohen H.J. Purification and binding properties of human platelet factor four. J. Biol. Chem. 1976, 251:4273-4282.
47. Sulpice E., Bryckaert M., Lacour J., Contreres J.O., Tobelem G. Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway. Blood 2002, 100:3087-3094.
48. Lasagni L., Francalanci M., Annunziato F., Lazzeri E., Giannini S., Cosmi L., Sagrinati C., Mazzinghi B., Orlando C., Maggi E., Marra F., Romagnani S., Serio M., Romagnani P. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J. Exp. Med. 2003, 197:1537-1549.
49. Aidoudi S., Bikfalvi A. Interaction of PF4 (CXCL4) with the vasculature: a role in atherosclerosis and angiogenesis. Thromb. Haemost. 2010, 104:941-948.
50. Gupta S.K., Singh J.P. Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J. Cell Biol. 1994, 127:1121-1127.
51. Gentilini G., Kirschbaum N.E., Augustine J.A., Aster R.H., Visentin G.P. Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (PF4), is associated with impaired downregulation of p21(Cip1/WAF1). Blood 1999, 93:25-33.
52. Nesmelova I.V., Sham Y., Dudek A.Z., van Eijk L.I., Wu G., Slungaard A., Mortari F., Griffioen A.W., Mayo K.H. Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J. Biol. Chem. 2005, 280:4948-4958.
53. Tanaka T., Manome Y., Wen P., Kufe D.W., Fine H.A. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat. Med. 1997, 3:437-442.
54. Cervi D., Pak B., Venier N.A., Sugar L.M., Nam R.K., Fleshner N.E., Klotz L.H., Venkateswaran V. Micronutrients attenuate progression of prostate cancer by elevating the endogenous inhibitor of angiogenesis, platelet factor-4. BMC Cancer 2010, 10:258.
55. Gupta S.K., Hassel T., Singh J.P. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc. Natl. Acad. Sci. USA 1995, 92:7799-7803.
56. Yang L., Du J., Hou J., Jiang H., Zou J. Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo. BMC Cancer 2011, 11:261.
57. Jouan V., Canron X., Alemany M., Caen J.P., Quentin G., Plouet J., Bikfalvi A. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood 1999, 94:984-993.
58. Lozano R.M., Redondo-Horcajo M., Jimenez M.A., Zilberberg L., Cuevas P., Bikfalvi A., Rico M., Gimenez-Gallego G. Solution structure and interaction with basic and acidic fibroblast growth factor of a 3-kDa human platelet factor-4 fragment with antiangiogenic activity. J. Biol. Chem. 2001, 276:35723-35734.
59. Hagedorn M., Zilberberg L., Lozano R.M., Cuevas P., Canron X., Redondo-Horcajo M., Gimenez-Gallego G., Bikfalvi A. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. Faseb. J. 2001, 15:550-552.
60. Bello L., Lucini V., Costa F., Pluderi M., Giussani C., Acerbi F., Carrabba G., Pannacci M., Caronzolo D., Grosso S., Shinkaruk S., Colleoni F., Canron X., Tomei G., Deleris G., Bikfalvi A. Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma. Clin. Cancer Res. 2004, 10:4527-4537.
61. Giussani C., Carrabba G., Pluderi M., Lucini V., Pannacci M., Caronzolo D., Costa F., Minotti M., Tomei G., Villani R., Carroll R.S., Bikfalvi A., Bello L. Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo. Cancer Res. 2003, 63:2499-2505.
62. Daly T.J., LaRosa G.J., Dolich S., Maione T.E., Cooper S., Broxmeyer H.E. High activity suppression of myeloid progenitor proliferation by chimeric mutants of interleukin 8 and platelet factor 4. J. Biol. Chem. 1995, 270:23282-23292.
63. Belperio J.A., Keane M.P., Arenberg D.A., Addison C.L., Ehlert J.E., Burdick M.D., Strieter R.M. CXC chemokines in angiogenesis. J. Leukocyte Biol. 2000, 68:1-8.
64. Hagedorn M., Zilberberg L., Wilting J., Canron X., Carrabba G., Giussani C., Pluderi M., Bello L., Bikfalvi A. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. Cancer Res. 2002, 62:6884-6890.
65. Griffioen A.W., van der Schaft D.W., Barendsz-Janson A.F., Cox A., Struijker Boudier H.A., Hillen H.F., Mayo K.H. Anginex, a designed peptide that inhibits angiogenesis. Biochem. J. 2001, 354:233-242.
66. Green C.J., Charles R.S., Edwards B.F., Johnson P.H. Identification and characterization of PF4varl, a human gene variant of platelet factor 4. Mol. Cell Biol. 1989, 9:1445-1451.
67. Struyf S., Burdick M.D., Peeters E., Van den Broeck K., Dillen C., Proost P., Van Damme J., Strieter R.M. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res. 2007, 67:5940-5948.
68. Vandercappellen J., Liekens S., Bronckaers A., Noppen S., Ronsse I., Dillen C., Belleri M., Mitola S., Proost P., Presta M., Struyf S., Van Damme J. The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo. Mol. Cancer Res. 2010, 8:322-334.
69. Zhang X., Chen L., Bancroft D.P., Lai C.K., Maione T.E. Crystal structure of recombinant human platelet factor 4. Biochemistry 1994, 33:8361-8366.